Startups
Inimmue is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation and immunology. Our pipeline currently includes several compounds and formulations thereof that modulate the innate immune system through Toll-like Receptors 4 and 7/8. Current preclinical programs are developing these assets for use in areas of critical patient need such as food allergy, allergic rhinitis, autoimmunity, as well as topically in cancer. Additionally, Inimmune applies its collective 50 years expertise in preclinical drug development to offer various contract services.
Inimmune was founded in early 2016. It is located in Missoula, MT and works in close collaboration with the Center for Translational Medicine at the University of Montana as well as several industry and several academia and industry partners.
Inimmune was founded in early 2016. It is located in Missoula, MT and works in close collaboration with the Center for Translational Medicine at the University of Montana as well as several industry and several academia and industry partners.
Overview
Location
United States, Montana, Missoula
Employees
11-50
Phone
+1 406-210-2162
Total raised
$22M
Founded date
2016
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 16, 2024 | SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems | WILMINGTON, Del., July 16, 2024 /PRNewswire/ -- SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of i... |
| Jul 11, 2020 | Inimmune Raises $22M in Series A | MISSOULA, MT, Inimmune announced today that it raised $22 million in Series A funding led by Two Bear Capital. >> Click here for more funding data on Inimmune >> To export Inimmune funding data to PDF and Excel, click here ... |
| Jul 10, 2020 | Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital | MISSOULA, Mont., July 9, 2020 /PRNewswire/ -- Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was... |
| Jul 10, 2020 | Inimmune Raises $22M in Series A Funding | Inimmune, a Missoula, Mont.-based biotechnology company developing immune therapies and components for more effective vaccines, raised $22m in Series A funding. The round was led by Two Bear Capital, a new firm based in Whitefish, Montana. ... |
Reviews 0
FAQ about Inimmune
When was Inimmune founded?
Inimmune was founded in 2016.
How much funding has Inimmune raised?
Inimmune has raised $22M in total across 1 funding round.
What has the press written about Inimmune?
Parsers VC has collected 5 articles mentioning Inimmune, among them “SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems” (Jul 16, 2024) and “Inimmune Raises $22M in Series A” (Jul 11, 2020).
Is Inimmune still active?
Yes, Inimmune is active; its latest activity on Parsers VC dates from Oct 22, 2024.